Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months - Pharmacy Practice News
C Diff Drug Development
Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting | Seres Therapeutics
The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022 - Business Wire
Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months - Infectious Disease Special Edition
Acurx Pharmaceuticals Nears Enrollment Milestone; Ibezapolstat Continues To Score Impressive Data Treating C. Difficile Infections ($ACXP) - Marketscreener.com
Acurx Pharmaceuticals was getting bullish interest at over $4.00. Now at $3.40ish, the herd should be pouncing. The interest is in ACXP's ibezapolostat, a novel, orally administered antibiotic being... | October 11, 2022
Acurx Pharmaceuticals Nears Enrollment Milestone; Ibezapolstat Continues To Score Impressive Data Treating C. Difficile Infections ($ACXP) - Digital Journal
Acurx Pharmaceuticals was getting bullish interest at over $4.00. Now at $3.40ish, the herd should be pouncing. The interest is in ACXP’s ibezapolostat, a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. While many potential new drugs show potential, this one can indeed be a game-changer in treating debilitating infections. […]
Clostridium Difficile Infections Pipeline Landscape Analysis of 25+ Companies by DelveInsight | Leading Players – Rebiotix, Seres Therapeutics, Acurx Pharmaceuticals, and Others - Digital Journal
DelveInsight’s, “Clostridium Difficile Infections Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline landscape. Clostridium Difficile Infections Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the […]
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems
Nature Reviews Drug Discovery - Discover the world’s best science and medicine | Nature.com
Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months - Infectious Disease Special Edition
@EuropeVaccine #ClostridioidesDifficile #cdiff
#ClostridioidesDifficile #cdiff— Wiep Klaas Smits (@SmitsLab) October 7, 2022
RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI) - Contagionlive.com
Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.
Ferring to present analyses for investigational microbiota based live biotherapeutic rbx2660 in patients with recurrent c diff
RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI) - MD Magazine
Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.
SER-109, CP101, VE303 for Treatment of Recurrent C. difficile Infection (rCDI) - Contagionlive.com
Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).
RBX2660 Could Heal Recurrent C Diff Patients, Physically and Psychologically
C diff patients live in fear of a recurrence, says gastroenterologist Paul Feuerstadt, MD. RBX2660 has entered the FDA pipeline and looks to end this vicious cycle.
.@AARP highlights #CDiff's potential to cause debilitating symptoms in patients and notes the work of @Rebiotix and @SeresTX to develop novel #microbiome therapeutics to treat this recurrent and often deadly GI infection. Read more:
.@AARP highlights #CDiff's potential to cause debilitating symptoms in patients and notes the work of @Rebiotix and @SeresTX to develop novel #microbiome therapeutics to treat this recurrent and often deadly GI infection. Read more: https://t.co/hmoseHtYhR— MTIG (@MTIG_News) September 27, 2022
Evaluation of Derivatives of (+)-Puupehenone against Clostridioides difficile and Other Gram-Positive Bacteria - PubMed
Patients receiving healthcare are at higher risk of acquiring healthcare-associated infections, which cause a significant number of illnesses and deaths. Most pathogens responsible for these infections are highly resistant to multiple antibiotics, prompting the need for discovery of new therapeutics …
P2X7 receptor blockade decreases inflammation, apoptosis, and enteric neuron loss during Clostridioides difficile toxin A-induced ileitis in mice
Our findings demonstrated that TcdA induced the upregulation of the P2X7 receptor, which promoted enteric neuron loss, S100B synthesis, tissue damage, inflammation, and cell death in the mouse ileum. These findings contribute to the future directions in understanding the mechanism involved in intest …
Evaluation of Derivatives of (+)-Puupehenone against Clostridioides difficile and Other Gram-Positive Bacteria
Patients receiving healthcare are at higher risk of acquiring healthcare-associated infections, which cause a significant number of illnesses and deaths. Most pathogens responsible for these infections are highly resistant to multiple antibiotics, prompting the need for discovery of new therapeutics …
Curcumin and capsaicin regulate apoptosis and alleviate intestinal inflammation induced by Clostridioides difficile in vitro
The results of the present study highlighted that CCM and CAP can modulate the inflammatory response and apoptotic effects induced by Tox-S from different clinical C. difficile strains in vitro. Further studies are required to accurately explore the anti-toxin activity of natural components, and the …
The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies - Endpoints News
Right around the beginning of the year, we got a close-up look at what happens after a boom ripples through biotech. The crash of life sciences stocks in Q1 was heard around the world. In the months since, we've seen the natural Darwinian down cycle take effect. Reverse mergers made
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20-25% of patients with a primary infection experience a recurrence, and …
FDA Committee Approves BLA for Rebyota (RBX2660) to Treat Recurrent C Difficile - Contagionlive.com
The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.
Microbiome Therapeutics Market Report 2022: Success Rate in C. Difficile Infection Driving Adoption - GlobeNewswire
Dublin, Sept. 19, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market Size, Share & Trends Analysis Report by Type (FMT, Microbiome Drugs),...
In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria - PubMed
The broad and potent in vitro antibacterial activity and lower risk of drug resistance suggested that OPS-2071 may be useful for enteric infections caused by major pathogens including quinolone-resistant Campylobacter.
A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections | Science Translational Medicine
Recursion adds FAP and C. diff clinical trials - Labiotech.eu
Recursion has initiated two additional clinical trials including its first in-house generated new chemical entity to enter the clinic.
Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
/PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the...
Destiny Pharma C. Difficile Treatment Program Gets Positive EU Feedback - MarketWatch
By Joe Hoppe Destiny Pharma PLC said Wednesday that the European Medicines Agency has given positive feedback on its proposed Phase 3 development program for...
GutMicrobiota Health on Twitter
Interesting new findings on the differences in nutrient use by our gut bacteria. Are we ready for personalized dietary advice based on microbiome preferences rather than food pyramids?https://t.co/qUH72R0ymM— GutMicrobiota Health (@GMFHx) September 8, 2022